{"Title": "Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study", "Year": 2016, "Source": "Endocr.-Relat. Cancer", "Volume": "23", "Issue": 3, "Art.No": null, "PageStart": 191, "PageEnd": 199, "CitedBy": 121, "DOI": "10.1530/ERC-15-0490", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84963958033&origin=inward", "Abstract": "\u00a9 2016 The authors Published by Bioscientifica Ltd.In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from the open-label extension (OLE). Patients with metastatic grade 1/2 (Ki-67 %10%) nonfunctioning NET and documented baseline tumour-progression status received lanreotide Autogel 120 mg (n=101) or placebo (n=103) for 96 weeks or until death/progressive disease (PD) in CLARINET study. Patients with stable disease (SD) at core study end (lanreotide/placebo) or PD (placebo only) continued or switched to lanreotide in the OLE. In total, 88 patients (previously: lanreotide, n=41; placebo, n=47) participated: 38% had pancreatic, 39% midgut and 23% other/unknown primary tumours. Patients continuing lanreotide reported fewer adverse events (AEs) (all and treatment-related) during OLE than core study. Placebo-to-lanreotide switch patients reported similar AE rates in OLE and core studies, except more diarrhoea was considered treatment-related in OLE (overall diarrhoea unchanged). Median lanreotide PFS (core study randomisation to PD in core/OLE; n=101) was 32.8 months (95% CI: 30.9, 68.0). A sensitivity analysis, addressing potential selection.", "AuthorKeywords": ["Anti-tumour effects", "Lanreotide Autogel", "Neuroendocrine tumours", "Open-label extension"], "IndexKeywords": ["Antineoplastic Agents", "Disease-Free Survival", "Humans", "Intestinal Neoplasms", "Neuroendocrine Tumors", "Pancreatic Neoplasms", "Peptides, Cyclic", "Somatostatin", "Treatment Outcome"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84963958033", "SubjectAreas": [["Endocrinology, Diabetes and Metabolism", "MEDI", "2712"], ["Oncology", "MEDI", "2730"], ["Endocrinology", "BIOC", "1310"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"55908628800": {"Name": "Caplin M.E.", "AuthorID": "55908628800", "AffiliationID": "60032819", "AffiliationName": "Royal Free Hospital"}, "7005087885": {"Name": "Pavel M.", "AuthorID": "7005087885", "AffiliationID": "60026245", "AffiliationName": "Charit\u00e9 University Medicine Berlin"}, "6602989744": {"Name": "\u0106wik\u0142a J.B.", "AuthorID": "6602989744", "AffiliationID": "60024421", "AffiliationName": "University of Warmia and Mazury"}, "7006021175": {"Name": "Phan A.T.", "AuthorID": "7006021175", "AffiliationID": "60027512, 60015023", "AffiliationName": "University of Texas, MD Anderson Cancer Center"}, "7005247364": {"Name": "Raderer M.", "AuthorID": "7005247364", "AffiliationID": "60012730", "AffiliationName": "University Hospital"}, "15736473100": {"Name": "Sedl\u00e1\u010dkova E.", "AuthorID": "15736473100", "AffiliationID": "60039507, 60016605", "AffiliationName": "Department of Oncology, First Faculty of Medicine, General Teaching Hospital"}, "7006048250": {"Name": "Cadiot G.", "AuthorID": "7006048250", "AffiliationID": "60020938", "AffiliationName": "Robert-Debr\u00e9 Hospital"}, "7004294756": {"Name": "Wolin E.M.", "AuthorID": "7004294756", "AffiliationID": "60027155, 60015941", "AffiliationName": "Markey Cancer Center, University of Kentucky"}, "35476469600": {"Name": "Capdevila J.", "AuthorID": "35476469600", "AffiliationID": "60012486", "AffiliationName": "Vall d'Hebron University Hospital"}, "7101839612": {"Name": "Wall L.", "AuthorID": "7101839612", "AffiliationID": "60013999", "AffiliationName": "Western General Hospital"}, "56962752000": {"Name": "Rindi G.", "AuthorID": "56962752000", "AffiliationID": "60031984", "AffiliationName": "Universita Cattolica del Sacro Cuore"}, "56269953800": {"Name": "Langley A.", "AuthorID": "56269953800", "AffiliationID": "60004781", "AffiliationName": "Ipsen"}, "56269989600": {"Name": "Martinez S.", "AuthorID": "56269989600", "AffiliationID": "60004781", "AffiliationName": "Ipsen"}, "15720832100": {"Name": "Gomez-Panzani E.", "AuthorID": "15720832100", "AffiliationID": "60004781", "AffiliationName": "Ipsen"}, "7005561095": {"Name": "Ruszniewski P.", "AuthorID": "7005561095", "AffiliationID": "60123796", "AffiliationName": "Paris Diderot University"}}}